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Background: In the past, clinical study participants have suffered from the experiments that they were subjected
to. Study subjects may not understand the study process or may participate in clinical studies because they do not
have access to medical care. The objectives of the present study were 1. to analyze the motives that might cause a
volunteer to participate as a study subject; 2. to identify the social-demographic profile of this study subjects; and 3.
to determine whether the motives to volunteer as a study subject are in accordance with the established legal and
ethical principles for research in Brazil.
Methods: Mixed-methods research was used (a qualitative-quantitative approach). A sample of 80 volunteers
underwent a semi-structured interview, which was based on a survey script that was elaborated from discussions
with key informants. The sample was randomly selected from a database of clinical study volunteers that was
provided by Brazilian clinical study centers. The interviews were recorded and transcribed. Descriptive statistics were
used for content analysis, including contingency tables with hypothesis testing.
Results: The motivations for clinical study participation were linked to types of benefit. The most frequently
encountered motivations were financial gain and therapeutic alternative. Altruism was not a common motivator,
and when altruism was present, it was observed as a secondary motivator. All participants reported that they
understood the Informed Consent Statement (ICS). However, only two parts of the form were remembered by all of
the volunteers: the section on being able to leave the study at any point and the section that stated that there
would be some responsible professional at their disposal for the entirety of the study.
Conclusions: The present study shows that study participants are primarily motivated by personal benefit when
volunteering to participate in clinical studies. Whether these study participants had an integral understanding of the
ICS is not clear.Background
A clinical study is an investigation that uses human sub-
jects to contribute to knowledge that can be applied to
benefit society. Clinical studies typically evaluate an
intervention that is applied to study subjects. The inter-
vention might be a drug, vaccine or therapeutic or surgi-
cal procedure [1]. Clinical studies are indispensable for
the progress of medicine, especially for the discovery of
new pharmaceuticals [2]. However, the use of human
subjects in these studies as a unit of analysis introduces
certain challenges [3].* Correspondence: solangenappo@gmail.com
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reproduction in any medium, provided the orIn the past, study participants have suffered from the
experiments that they were subjected to. One example is
the experiments that were performed on prisoners dur-
ing World War II [4], which generated a series of
tragedies that are still remembered today. Those experi-
ments violated the ethical rules that are currently ap-
plied to clinical studies [5,6].
Past violations have contributed to the development of
mechanisms to protect human subjects [7]. The scien-
tific community was made aware of these violations, and
various regulations have been elaborated to protect
human rights and the integrity and dignity of individuals
participating in biomedical research [8].
However, the unethical studies of the past have left a
strong impression and are still referenced in developing
countries. In Brazil, the general perception is that theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the term “human guinea pig” is commonly used to de-
scribe clinical study participants [9].
The basic principles of bioethics (autonomy, benefi-
cence, non-maleficence and justice) [10] may be violated
in clinical studies on human subjects in such developing
countries as Brazil and may be a source of bias within the
study [11]. The characteristics of study populations from
these countries, such as poverty, illiteracy, lack of educa-
tion and lack of availability/access to health care, may cre-
ate inherent bias. In addition, several authors warn that
populations in developing countries require special pro-
tection, due to these factors [12]. These study subjects
may not understand the study process or may participate
in clinical studies because they do not have access to med-
ical care. Other authors have noted that these study parti-
cipants are more susceptible to coercion and may more
easily become volunteers in clinical studies [13].
Fortunately, it is clear that there has been increased
emphasis on bioethics in Brazil in relationship to clinical
studies of human subjects. The Clinical Study Regulation
was created under Resolution 196/96 of the National
Health Council (Conselho Nacional de Saúde-CNS) of
the Health Ministry. As a result, the ethical evaluation
process that a clinical study must pass is sufficiently
rigorous and is in accordance with national laws [14]. In
addition to the bioethics evaluation performed by the
Ethics in Research Committee (Comitê de Ética em
Pesquisa - CEP) of the study institution, international
studies must also receive consent from the National
Commission of Ethics in Research of the National
Health Council (Comissão Nacional de Ética em Pesquisa
do Conselho Nacional de Saúde - CONEP) and the
National Sanitary Monitoring Agency (Agência Nacional
de Vigilância Sanitária - ANVISA) [5].
All subjects receive an Informed Consent Statement
(ICS). This document explains in accessible language the
research details to ensure that that the subject understands
the procedures, risks, discomforts, benefits and rights
involved and makes an autonomous decision [15,16].
Despite the rigor of these interventions, the idea per-
sists that study subjects in Brazil participate in clinical
studies for the wrong reasons [9].
The objective of the present study is to identify the
specific motivators that inspire Brazilian volunteers to
participate in clinical studies and to describe the demo-
graphic profile of these study subjects. In addition, we
will evaluate whether the motivations are in accordance
with established ethical and legal principles.
Methods
Rationale for the choice of methodology
A multi-methods study [17] with qualitative and quanti-
tative phases was used. Qualitative methods were usedto identify the motivations for study participation, focus-
ing on interviewees perception and behaviors [18].
Quantitative analyzes were used to compare the motiva-
tors for research participation between groups and the
variables that are associated with this motivation.
Recruitment of the participants
A convenience sample was used. Three clinical research
centers that conduct Phase I (bioequivalence) and Phase
III (therapeutic) studies provided the records of subject
participants. One center was in São Paulo, another was
in Campinas and the third was in Goiania. In Brazil,
there are few Phase I studies. Therefore, we considered
bioequivalence studies, which use healthy volunteers to
compare the bioavailability of a generic medicine to a
reference medicine, to be Phase I studies. The partici-
pants were selected from 10 lists with a total of 500
volunteers each and were contacted by telephone for a
personal interview in the Federal University of São Paulo
(Universidade Federal de São Paulo, UNIFESP). These
lists were composed of volunteers who participated in
previous studies when they left permission to be con-
tacted for future studies. They included the names of
participants of studies conducted by the centers for the
two years previously. The participation rate was 89%. In
total, 90 participants were contacted (30 from each
center), and 80 agreed to participate. The 10 refusals to
participate included 4 men and 6 women, from the 3
centers.
Procedure for translating the data
The interviews were conducted in Portuguese being
recorded and later on transcribed and analyzed. The
final result was translated into English by AJE (American
Journal Experts) a site of experts from the scientific
community with expertise in the two languages (English
and Portuguese). The quotes were back translated in
order to ensure the fidelity of the interviewees’
statements.
Sample size
The sample was composed of 80 volunteers who had
participated in at least one Phase I or Phase III clinical
study. The sample size was limited by the qualitative in-
depth interview. Furthermore, this pilot study was not
intended to be representative of the entire population of
study participants. Rather, this study was designed to
identify the main motivations that lead to clinical study
participation and whether these motivators differ by re-
search phase.
Key informants (KI)
Key informants were people with specific knowledge
regarding the study population and who were prepared
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the theme of the research, noting the peculiarities of the
participants [19]. A total of ten KIs were interviewed.
Three were principle investigators from the study cen-
ters, two were clinical study center coordinators, one
was a representative of the Brazilian Society of Clinical
Study Professionals (Sociedade Brasileira de Profissionais
de Pesquisa Clinica-SBPPC), one was a representative of
the Brazilian Association of Clinical Study Representa-
tive Organizations (Associação Brasileira de Organiza-
ções Representativas de Pesquisa Clínica-CRO), one was
a regional director of clinical operations of the pharma-
ceutical industry and two were doctors responsible for
conducting the studies in public and private reference
hospitals. The interviews with the KIs were unstruc-
tured, conversational interviews [20,21]. They were
recorded, transcribed, analyzed and provided informa-
tion that could be used to develop interview questions
for the clinical study subjects and to aid in understand-
ing the discussions of the interviewed individuals [19].
These interviews allowed for comparative analysis of
the motivations for participation in research studies
according to subjects and KIs.
Data collection instrument
The categories that emerged from the discussion with
the KIs were used to describe the study subject volun-
teer profile and topics in the survey script. This survey
script included sociodemographic data (age, gender and
education), type of clinical study (Phase I or III), the
involved pathology and location, the number of times
that the volunteer participated in clinical studies, the
motivation for participation, information concerning the
ICS (whether it was introduced correctly and whether
the volunteer could explain the study topic and remem-
ber the ICS), compensation received for participation
and recruiting vehicles (how the volunteer found out
about the study). Socioeconomic class was measured
using the ABEP scale (Brazilian Association of Research
Companies - Associação Brasileira de Empresas de Pes-
quisa), which takes into consideration the education
level of the head of the household and ownership of
assets [22]. This scale was used to sort participants into
standardized subgroups labeled from A to E where A
was the highest economic strata. Mean family income
(MFI) at the E-level of the ABEP index is very low
(below a 'living wage' level considered acceptable for
families in the US), whereas a D-level family enjoys a
MFI value roughly 1.5 times the E-level MFI. The C-
level MFI is roughly 2–3 times the E-level value, A-level
and B-level is approximately 27 times and 9 times the E-
level MFI value respectively.
The anonymous interviews were semi-structured, in-
depth conversations that were recorded with the consentof the respondent. The interviews were approximately
40 minutes in duration, and the participants were com-
pensated R$20.00 (twenty reais) upon completion of the
interview.
Analysis of the results
Qualitative analysis of the interviews
After transcription, the interviews were submitted for
content analysis, as proposed by Taylor and Bogdan [23]
and Bardin [24] in accordance with the following steps:
Initial reading
The initial reading allowed for the formation of general
impressions.
Preparation of the material
The material was prepared by separating and categoriz-
ing the responses according to topic. This material gave
rise to independent archives for each script item: age,
gender, education level, motivation for participation,
study type, number of times the individual participated
in clinical studies, method of recruitment, compensation
for participation, understanding of the ICS and socioeco-
nomic class. Each item included 80 responses that corres-
pond to each sample constituent. With this information,
the categories were constructed.
Treatment of the results
The frequencies were calculated, allowing for interpret-
ation. In the present study the triangulation technique
was used [19]. Each interview was coded by more than
one researcher to ensure the consistency of interpretations
and increase the reliability of the categories. Excerpts from
the interviews with KIs and study subjects appear in italics
in the results.
Statistical analysis
Hypothesis tests were conducted for each of the script
variables to compare the characteristics and motivations
of Phase I and Phase III study subjects. After codifying
the answers from the qualitative phase, each theme was
analyzed to generate up to 5 response categories. These
variables were tested for the homogeneity of the distri-
bution of responses across categories. The Student’s t-
test was used to evaluate average age, study phase and
research motivation. The Pearson’s chi-square test or the
Fisher’s exact test was used for the categorical variables.
A significance level of 5% was adopted, and Stata version
11 software was used to perform the analyses.
Ethics
The protocol was reviewed and approved by the
Universidade Federal de São Paulo (UNIFESP) Re-
search Ethics Committee (Protocol #0870/10), with
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decline to participate, to leave questions unanswered, and
that they could interrupt their participation at any time,
according to the Declaration of Helsinki. No one of the
researchers occupy dual role (they were not clinicians or
clinical researcher’s managers).Results
There was a predominance of women among the respon-
dents (58%). Table 1 shows that the majority completed
high school or college (approximately 90%), were less than
50 years of age (72%), were in either socioeconomic class
B or C (84%) and had participated in only one clinical
study (63%).Table 1 Sociodemographic data for the 80 respondents
according to research phase
Characteristics Phase I N (%) Phase III N (%) TOTAL N
Gender
Male 19 (47.5) 27 (67.5) 46
Female 21 (52.5) 13 (32.5) 34
Education
Primary 4 (10.0) 4 (10.0) 8
High School 17 (42.5) 18 (45.0) 35
College 18 (45.0) 18 (45.0) 36
NR 1 (2.5) 0 (0) 1
Socioeconomic class1
A 0 (0) 0 (0) 0
B 11 (27.5) 4 (10.0) 15
C 28 (70.0) 24 (60.0) 52
D 1 (2.5) 9 (22.5) 10
E 0 (0) 3 (7.5) 3
Number of studies
1 24 (60.0) 26 (65.0) 50
2 1 (2.5) 11 (27.5) 12
3 9 (22.5) 2 (5.0) 11
4 or more 6 (15.0) 1 (2.5) 7
Age (years)
≤ 20 1 (2.5) 0 (0) 1
21 - 30 19 (47.5) 1 (2.5) 20
31 - 40 11 (27.5) 4 (10.0) 15
41 - 50 8 (20.0) 14 (35.0) 22
51 - 60 0 (0) 9 (22.5) 9
61 or more 0 (0) 12 (30.0) 12
NR 1 (2.5) 0 (0) 1
NR= No Response.
1A was the highest economic strata. Mean family income (MFI) at the E-level
of the ABEP index is very low (below a 'living wage' level considered
acceptable for families in the US), whereas a D-level family enjoys a MFI value
roughly 1.5 times the E-level MFI. The C-level MFI is roughly 2–3 times the E-
level value, A-level and B-level is approximately 27 times and 9 times the E-
level MFI value respectively.Analysis of the interview
Motivation to participate
Content analysis of the interviews identified motivating
factors for participation in clinical studies. Figure 1 lists
the main motivation for participation categories that
emerged from the discussions with the KIs and study
subjects. Both groups identified the therapeutic option
and financial compensation as key motivators, suggest-
ing that the KIs understood the motivations of the
volunteers.
Therapeutic option
Key informants
Opinion of the KIs versus the study subjects
According to the KIs, the therapeutic option to have
access to a new treatment and the hope that this new
drug can produce an improvement is a motivator to en-
gage in clinical studies for potential experimental treat-
ments. The discussions with the KIs in the following
transcripts reveal the opinions of these professionals.
The group of patients, because they already have the
illness, is always searching for something better, a new
treatment. They submit themselves to the collateral
effects of the medication to try a new medication, i.e.,
for cancer.
Others opt to participate in the study because they do
not have another therapeutic option. These cases are
more common in oncology and rare illnesses with few
conventional treatment options.
Study subjects
Motivation for participating in a clinical study according
to study participants:
According to study subjects, the therapeutic option is
a strong motivator to enroll in a clinical study. The po-
tential benefit of a new medication was the most cited
motivator. However, it is worth noting that this motiv-
ator is restricted to those volunteers with some type of
pathology (in this case, Phase III study subjects). The
following excerpt is from an interview with a study par-
ticipant:
Motivation? It was for the benefit itself because it was
a problem that I have. I thought: let’s do it!
Financial compensation
Key informants
According to the KIs, financial compensation influences
a volunteer’s decision to participate in a clinical study,
especially among healthy volunteers. Although the
Brazilian legislation only allows for compensation for
time spent in the study, this remuneration is often
Key Informants Study Subjects
Therapeutic option Therapeutic option
Financial compensation Financial compensation
Access to healthcare
Altruism Altruism (secondary motivation)
Other
Figure 1 Principal motivators for participation in a clinical study according to KIs and study subjects.
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I believe that the healthy volunteers, in Phase I studies
and in some other situations are motivated by a
financial compensation, although in accordance with
resolution 196 we cannot pay a Study Subject in
Brazil, but in some way this compensation is the
greatest motivation to participate in the study.
There is a camouflaged payment [compensation for the
work-loss day], but many times it is much higher that
the workday compensation.
Study subjects
Healthy volunteers identified compensation as the prin-
cipal motivation for participation in a study. The major-
ity of volunteers did not want to reveal the amount that
they received for participating in these studies.
It is not the first time that I have participated. They
pay well, and I have confidence in the place and it is
good because they do several examinations, and I a
find out about how my health is.
Access to healthcare
Key informants
According to KIs, many study subjects enter clinical
studies because they believe that they will have improved
access to health care and better quality of care. The sub-
jects believe that they will be better able to check up on
their health and will be able to avoid the time that they
would spend in the public health sector. Moreover, the
ability to call a study physician at any time is attractive
to these patients.
In general the people, who participate of clinical studies,
participate in research projects because they receive
excellent attention and a healthcare option that is
frequently better than the healthcare medical plans.
The patient feels truly taken care of, this is very
difficult for me to assume, but it is what happens, the
easiness in the attendance, the patients undergoexaminations, they are taken care of with a special
attention by the doctor. . .
The KIs mentioned access to healthcare as one of the
main reasons for engaging in a clinical trial. However,
the clinical trial participants did not evaluate it the same
way. They acknowledge access to healthcare as a benefit
but secondarily to other reasons that they consider more
important for participating in a clinical trial, such as: fi-
nancial advantage or therapeutic option.
Altruism
Key informants
The KIs believed that a small portion of the study sub-
jects altruistically engage in these studies to improve the
lives of others.
I believe that there is an emotional component to this
condition that emerges. For example, a father that
volunteers for an AIDS vaccine because he lost a child
to the disease.
Study subjects
Some of the respondents mentioned the possibility of
helping other people as a motivator for participating but
always as secondary motivation.
It was to improve my knee and also to help in the
study.
First, because I have arthritis, and my healthcare plan
was very bad. . .. and second, because I am helping the
researcher, and who knows, maybe humanity.
Other motivations
Key informants
The KIs also commented that the possibility for volun-
teers to make friends with people of a similar age and
health status might lead them to participate.
(. . .) The elderly women created a certain community
then, they met in the waiting room, they exchanged
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outside of the clinic.
The possibility of receiving the test medication for the
entire illness period, even after completing the study,
was another motivation that was mentioned by the KIs.
Study subjects
Few study subjects cited motivations other than a new
therapeutic option and financial compensation. However,
some added additional motivators, such as the recom-
mendation of their personal physician to participate in
the study.
I wanted to try another treatment. The ones that I had
tried had no effect. That was when my doctor said
that there might be a good opportunity for me to
participate in a study for a new arthritis medication.
Informed Consent Statement (ICS)
All the interviewed subjects declared that they had read
and understood the ICS. They also reported that when
they were unsure that there was a professional available to
help them. However, when asked if they could remember
the principal points of the ICS, a number of participants
did not remember any of the content. Among those that
remembered some parts of the ICS, none mentioned the
potential risks of the study in which they participated.
That I could quit whenever I wanted to, and that I
could speak with a doctor at any time.
I could stop when I wanted to, that I would take
laboratory medicine with a name that I can’t
remember. . .I had to do the exercises correctly.
I gone through the entire interview, I did all the
examinations, but I do not remember what was
written, I enrolled with the desire to resolve this
[health] problem.
Results of the statistical analysis
Table 2 shows that participants in different types of stud-
ies have different motivations to participate (p < 0.0001).Table 2 Motivators for clinical study participation
according to study phase (N=80)
Motivators Phase I
(n = 40)
Phase III
(n = 40)
n (%) n (%) P - value2
< 0.0001
Financial Compensation 36 (94.7) 2 (5.3)
Therapeutic option 0 (0.0) 34 (100.0)
Other1 4 (50.0) 4 (50.0)
1 Including altruism, knowledge, medical indication and access to healthcare; 2
Fisher exact test.For example, 94.7% of respondents that were motivated
by financial compensation were Phase I study subjects.
Conversely, 100% of the respondents who were searching
for a therapeutic option were Phase III study subjects.
Other motivations such as altruism and access to the
healthcare were mentioned but were not the main moti-
vators. Only 4% of participants alleged that these were
the principal motivators.
The average age of participants (Table 3) was signifi-
cantly different depending on the phase of the clinical
study (p <0.0001). Those that participated in Phase I
studies were younger (average age: 32 years; 95% CI:
28.7-34.8) than participants in Phase III studies (average
age: 53 years: 95% CI: 49.1 - 56.0%).
The average age varied by study purpose (p < 0.0001).
The bioequivalence and medication studies had the
youngest average ages (average age: 31.5; SD= 9.3). In
this case, all were phase I study subjects (Table 4).
Most of the volunteers from both phases belonged to
class C. However, the proportion of class D and E sub-
jects varied according to study phase. Only 2.5% of parti-
cipants from Phase I clinical studies belonged to the
classes D and E. None of the respondents belonged to
class A (Table 5).
No statistically significant differences in the proportions
of men to women when stratifying for study purpose or
research phase. In addition, there were no differences in
social class or education level when stratified by motiv-
ation for entering the study (data not shown).
Discussion
Developing nations are participating in multi-center
clinical studies at increasing rates. This participation is
due to the reduced operational costs, ease of recruiting
study subjects, ability to conduct research and regulatory
capacity of these countries [26]. According to several
authors, this shift is primarily due to economic consid-
erations [20,27], suggesting that volunteers for clinical
studies in developing countries are “guinea pigs” [9].
Therefore, there should be heightened concern for the
ethical requirements to conduct a clinical study in these
areas [21]. Further innovation in the pharmaceutical
field requires these countries to be able to conduct clin-
ical studies ethically. It is essential for international stud-
ies to be conducted in Brazil to advance the body of
knowledge [2].Table 3 Average ages of the study subjects, according to
research phase and motivator (N=79)
N Age (average) CI 95% P-value1
<0.0001
Phase I 39 32 28.7 - 34.8
Phase III 40 53 49.1 - 56.0
Using Student’s t-test.
Table 4 Average age, according to type of study (N=79)
Type of study N Age (average) Standard deviation p-value2
< 0.0001
Arthritis/
osteoarthritis
24 56.7 8.4
Bioequivalence 39 31.5 9.3
Insomnia 10 48.2 12.4
Other1 6 43.3 9.9
Included studies of menopause and temporomandibular pain;
ANOVA.
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velopment in this field, Brazil is far from being consid-
ered a major research center. The idea that Brazilian
research participants are guinea pigs is not justified.
Brazil conducts only 1.8% of total global clinical studies
(n =1417). In contrast, the United States performs the
majority of clinical studies; 54.3% of global clinical stud-
ies are conducted in the US (n= 41917) [25].
These numbers demonstrate that Brazil is still not
an important clinical research center, despite having
characteristics that would be conducive for performing
studies. Therefore, it is inappropriate to accuse Brazil of
being the supplier of guinea pigs for clinical studies [9].
However, this finding should not decrease the focus on
ethical concerns for clinical studies. These advances must
be made rationally and should avoid unfounded critiques
and prejudices of emerging countries.
Altruism should be the main reason for a subject’s de-
cision to participate in a research study28). Ideally, the
volunteer is capable of making decisions based on the
information provided about the proposed study, and
understands the purpose, risks, benefits, alternatives and
requirements of the study. After receiving this informa-
tion, the volunteer is able to decide to participate, free
from coercion or improper influences [28]. However,
there is concern that the benefits may interfere with the
study subject’s evaluation of the risks [21].
The results of the present study, although preliminary,
show that health and financial benefits are the primary
motivators for respondents to become study subjects.
Individuals from higher socioeconomic classes were moreTable 5 Socioeconomic class (based on the ABEP scale),
stratified by study phase (N=80)
Socioeconomic class Phase I (n=40) Phase III (n=40)
n (%) n (%) p-value1
A 0 (0) 0 (0) < 0.0005
B 11 [25] 4 [10]
C 28 (70) 24 (60)
D 1 (2.5) 9 (22.5)
E 0 (0) 3 (7.5)
1 Fisher’s exact test.likely to cite altruism as a secondary motivator after eco-
nomic advantage (Phase I) or therapeutic option (Phase
III). The same motivations were also identified by the KIs.
Although several authors insist that these motivators
are more common in developing countries[21], studies
demonstrate that they are found in study subjects
throughout the world [29,30].
In a review by Stunkel and Grady [29], 12 of 13 studies
showed that financial motivation was the main reason to
participate in studies. One volunteer from these studies
comments, “Nobody is Robin Hood to make the good for
the society.” In the studies where the participants
affirmed that compensation was the main motivator, no
participants refused payment [31].
In a study of the motivations for healthy subjects to
participate in research Vrhovac et al. [32] found that al-
most 80% reported compensation as the primary motiv-
ator. However, in that study, 20.6% of the volunteers
denied that the money was the principal reason and
identified humanitarian motivations and the desire to
contribute to society. The key informants for the present
study also mentioned altruism; however, it was only
mentioned in exceptional situations.
Alternatively, there are study subjects that believe that
compensation should be commensurate with the risks of
the study and that compensation should be increased for
invasive procedures, such as drawing blood [33].
Almeida et al. [34] found that volunteers with low
education and low socioeconomic status were more
likely to cite financial motivations to participate in a
clinical study.
In this study, we did not find this association; there
was no difference in education level between Phase I
and Phase III participants. However, participants in a
higher socioeconomic class were more likely to partici-
pate in Phase I studies (Table 5) (thus, according to
Table 1, they were more likely to be healthy volunteers
participating for financial reasons). These findings are in
agreement with those of Kass et al. [30], who found that
Caucasians with a higher education level were more
likely to be motivated by financial benefits. These find-
ings are in contrast to the beliefs of some authors who
say that compensation attracts low-income volunteers,
resulting in a disproportionate number of poor people
participating in clinical studies [35].
Gelderen [36] found that the youngest volunteers were
the most likely to mention money as the primary motiv-
ator to participate, which is a finding that was repro-
duced in our study (average age of 32 years in Phase I
participants). This result is not surprising, as younger
people might not be as financially established and may
be looking for ways to earn money. Moreover, Phase I
participants are required to be healthy, which is a criter-
ion that is more common among younger adults.
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for participation in clinical studies was to search for a
new treatment, a motivator that was also mentioned by
the KIs. Grecco and Diniz [37] have noted that clinical
study volunteers in developing countries see participa-
tion in clinical studies as an opportunity to receive
better healthcare, easier access to more expensive la-
boratory examinations and novel drugs. According to
Grecco and Diniz, these motivations constitute a conflict
of interests. It is worth noting that Brazilians have uni-
versal access to the Unified Healthcare System (Sistema
Único de Saúde – SUS), which is funded by the federal
government [38]. However, access to this system does
not limit the interest in clinical studies, perhaps due to
the quality of the services or the degree of individualized
attention.
Cabral et al. [1] have noted that in the research envir-
onment, the physician-patient relationship is inverted.
Classically, the physician satisfies the needs and interests
of the patient. However, in a clinical study, the patient
satisfies the interests of the study and thus the re-
searcher. Lackey [27] adds that the researcher, for the
advancement of the study, must treat these subjects as
scientific objects submitted to the laws of cause and ef-
fect. The study subjects may not understand this distinc-
tion and may continue to participate in the study
expecting a cure when, in reality, the medicine may not
have any effect.
Canvin and Jacob [39] observed a group of volunteers
for a study of epilepsy and noted that these volunteers
were happy to help others only when they could also
help themselves. The authors called this behavior “weak
altruism,” and McCann et al. [40] have called this behav-
ior “conditional altruism.” According to these authors,
the desire to help others or to contribute to the body of
knowledge does not lead a volunteer to participate in a
study unless that volunteer perceives that his participa-
tion in the study may benefit him personally.
The Informed Consent Statement (ICS), which is
required under Resolution 196/96 (CNS/196), is provided
for the volunteer to inform him about the study, including
the associated risks and the responsibilities of those
involved. The ICS is indispensable to the ethical conduct
of the research. According to a number of authors, volun-
teers do not always pay enough attention to the ICS. This
oversight may occur because the volunteer trusts the doc-
tor (or at least the role of the doctor) and does not take
into consideration the role of the doctor as a researcher,
that is, the doctor is not necessarily focused on meeting
the patient’s global health needs [27]. Additionally, the
patient may overestimate the benefit for himself and lose
the ability to weigh the disadvantages of the study [41]. Fi-
nally, the volunteer may not understand the ICS because
of a low educational level [42]. In the present study, mostvolunteers had a good education, and all declared that
they understood the ICS. However, when they were ques-
tioned about the study details, they only remembered the
possibility of speaking with a doctor and the possibility of
leaving the study. None of the subjects mentioned the dis-
advantages of the study, such as the risks or potential ad-
verse reactions to the medicine. These findings may
indicate that the volunteers did not adequately understand
the ICS. It is worth noting that a portion of the respon-
dents did not remember that some items of ICS may be
limited to the time that they participated in the study. The
more “comfortable” situations associated with the study
were remembered, while the situations associated with
risks were not mentioned. However, the date of last par-
ticipation in a clinical trial was not questioned, which may
constitute a limitation in analysis of the data.
Conclusion
In the present study, study volunteers were motivated by
some type of personal benefit from participating in a
study (especially financial or therapeutic benefits), which
is a finding has been observed in clinical study partici-
pants in other countries. According to several authors,
this finding is accentuated in emerging countries, such
as Brazil, due to the limitations of the health care sys-
tems, even despite the universal access provided by the
SUS. Altruism was not a common motivator, and when
it was mentioned, it was never the primary reason. Some
have called type of motivation this “conditional altru-
ism”. The ICS was understood by all participants; how-
ever, the degree of understanding may have been
limited. None of the subjects remembered the text refer-
ring to the potential harms of the procedure or medi-
cine. The authors hypothesize that this behavior results
because the individuals participate out of self-interest,
rather than altruism.
Study limitations
This study was a preliminary study with a qualitative-
quantitative approach. The study sampled 80 partici-
pants and was not representative of the total population
of clinical study participants. Another limitation is the
fact that those who refused to participate in the research
were not surveyed.
Study strengths
This study demonstrates that personal benefit is the pri-
mary motivation for volunteers to participate in clinical
research. However, we argue that this motivation seems
to be universal and is not limited to developing coun-
tries. Moreover, the theory that financial compensation
disproportionately attracts poor volunteers has not been
supported. Furthermore, the fact that study participants
are primarily motivated by personal benefit does not
Nappo et al. BMC Public Health 2013, 13:19 Page 9 of 9
http://www.biomedcentral.com/1471-2458/13/19suggest that they do not evaluate the risks of participa-
tion. For further consideration, if we consider altruism
to be the only ethically acceptable motivation for study
participation, must we evaluate whether the principle of
autonomy has been disrespected?
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